<unk>  is a metabolic abnormality that leads to an increase in the plasma concentrations of cholesterol and triglycerides. Lipoprotein abnormalities can be classified on the bases of the pattern of change in the lipoprotein levels, etiology, and the type of lipid that is increased.<unk>  can be caused by endocrine disorders such as hypothyroidism, diabetes mellitus, medications such as protease inhibitors or antihypertensive, anabolic steroid use, cholestasis, and autoimmune disorders. While screening the disease it is important to identify the cardiovascular disease risk factors among patients. Framingham Risk Assessment Tool and Reynolds Risk Score are utilized to screen for CVD risk and follow-up screening varies with the diabetes mellitus status, patient age, and gender. Treatment involves setting the target cholesterol levels of < 200 mg/dL, and LDL-C levels of < 70 mg/dL for very high risk patients OR < 100 mg/dL for all other patients. HDL should be as high as possible. Lifestyle recommendations is the first step in treatment before pharmacotherapy. Pharmacotherapy includes monotherapy such as statins (monitor AST, ALT, and CK); fibrates; niacin; and bile acid sequestrants. Uncontrolled<unk>  requires combination therapy. Regular follow up with labs to access drug side effects and monitoring patient health is vital.
Dyslipidemia
Hypertriglyceridemia
Hypolipoproteinemia
Hypercholesterolemia
Hypocholesterolemia
Glucose intolerance
Hyperlipoproteinemia
Xerosis